Conclusion In DLBL patients, mortality was affected by the RDI of R-CHOP as the initial treatment and the retention of high RDI could be crucial, especially in elderly patients. PF-573228 order To optimize the RDI of conventional chemotherapy in order to achieve better outcomes for patients with DLBL, further investigation of RDI will be required. Acknowledgements We thanks for clinical
research nurse. Yukari Umemoto (Hematology, Graduate School of Medicine, Osaka City University, Osaka, Japan) for assistance in obtaining clinical data and follow-up information. References 1. Fisher RI, Gaynor ER, Dahlberg S, Oken MM, Grogan TM, Mize EM, Glick JH, Coltman CA Jr, Miller TP: Comparison of a standard regimen
(CHOP) with three intensive chemotherapy regimens for advanced non-Hodgkin’s lymphoma. N Engl J Med 1993, 328: 1002–6.CrossRefPubMed 2. International Non-Hodgkin’s Lymphoma Prognostic Factors Project: A predictive model for aggressive non-Hodgkin’s lymphoma. MK-0457 order N Engl J Med 1993, 329: 987–94.CrossRef 3. Epelbaum R, Haim N, Ben-Shahar M, Ron Y, Cohen Y: Dose intensity analysis for CHOP chemotherapy in diffuse aggressive large cell lymphoma. Isr J Med Sci 1990, 24: 533–8. 4. Kwak LW, Halpern J, Olshen RA, Horning SJ: Prognostic Enzalutamide see more significance of actual dose intensity in diffuse large-cell lymphoma: Results of a tree-structured survival analysis. J Clin Oncol 1990, 8: 963–77.PubMed 5. Epelbaum R, Faraggi D, Ben-Arie Y, Ben-Shahar M, Haim N, Ron Y, Robinson E, Cohen Y: Survival of diffuse large cell lymphoma. A multivariate analysis including dose intensity variables. Cancer 1990, 66: 1124–9.CrossRefPubMed
6. Lepage E, Gisselbrecht C, Haioun C, Sebban C, Tilly H, Bosly A, Morel P, Herbrecht R, Reyes F, Coiffier B: Prognostic significance of received relative dose intensity in non-Hodgkin’s lymphoma patients: Application to LNH-87 protocol: The GELA (Groupe d’Etude des Lymphomes de l’Adulte). Ann Oncol 1993, 4: 651–6.PubMed 7. Bosly A, Bron D, Van Hoof A, De Bock R, Berneman Z, Ferrant A, Kaufman L, Dauwe M, Verhoef G: Achievement of optimal average relative dose intensity and correlation with survival in diffuse large B-cell lymphoma patients treated with CHOP. Ann Hematol 2008, 87: 277–83.CrossRefPubMed 8. Coiffier B, Lepage E, Briere J, Herbrecht R, Tilly H, Bouabdallah R, Morel P, Neste E, Salles G, Gaulard P, Reyes F, Lederlin P, Gisselbrecht C: CHOP chemotherapy plus rituximab compared with CHOP alone in elderly patients with diffuse large B-cell lymphoma. N Engl J Med 2002, 346: 235–42.CrossRefPubMed 9.